<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139665">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060682</url>
  </required_header>
  <id_info>
    <org_study_id>EU100</org_study_id>
    <nct_id>NCT02060682</nct_id>
  </id_info>
  <brief_title>Post-Market Registry of the ACIST CPM System and Navvus Catheter in Clinical Practice</brief_title>
  <acronym>ADVANCE-EU</acronym>
  <official_title>Post-Market Registry of the ACIST Cardiovascular Pressure Measurement (CPM) System and Navvus Catheter in Clinical Practice-ADVANCE-EU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acist  Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acist  Medical Systems</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <authority>France: French Data Protection Authority</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry will collect real-world clinical evidence on the performance, safety, and
      usability of the ACIST CPM System and NAVVUS Catheter when used in accordance with approved
      labeling in a European commercial setting. Up to 60 subjects will have Fractional Flow
      Reserve (FFR) measurements of coronary lesions attempted with the CPM System and NAVVUS
      Catheter.  All subjects will receive diagnostic treatment according to clinical indications
      and center standard practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no protocol-specific procedural requirements for this registry. Enrolled subjects
      will undergo a diagnostic angiography procedure including an FFR measurement with the CPM
      System and NAVVUS Catheter according to the center standard of care and the Instructions for
      Use of the CPM System and Navvus Catheter.  Participants will be followed for the duration
      of hospital stay, an expected average of 1 day.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>From enrollment through hospital discharge, an expected average of 1 day.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Procedural success is defined as the ability of the ACIST CPM System and NAVVUS Catheter to acquire FFR measurement without adverse device effect or device malfunction.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Navvus Catheter FFR</arm_group_label>
    <description>The Navvus Catheter is a rapid exchange microcatheter with a pressure sensor at the distal tip that measures Fractional Flow Reserve measurements to guide PCI treatment strategy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Navvus Catheter FFR</intervention_name>
    <description>Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).</description>
    <arm_group_label>Navvus Catheter FFR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects 18 years of age or older, in whom FFR measurement is indicated to guide PCI
        strategy and use of the ACIST CPM System and Navvus Catheter is attempted.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 18 years of age or older in whom FFR measurement is indicated to guide
             percutaneous coronary intervention (PCI) strategy and use of the ACIST CPM System and
             Navvus Catheter is attempted.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Lefèvre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Privé Jacques Cartier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennis Crane</last_name>
    <email>dennis.crane@acistmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debra Jovanovich</last_name>
    <email>debra.jovanovich@acistmedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Privé Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thierry Lefèvre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>St. Denis</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johann Wolfgang Goethe Universität</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Fichtlscherer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda gAG</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Volker Schächinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Münzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ramon Lopez Palop, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fractional Flow Reserve</keyword>
  <keyword>Rapid Exchange</keyword>
  <keyword>Catheter</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
